Pharma Friday – February 9

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia Last month, Spruce Biosciences, announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH). Spruce Biosciences is […]

To view the full Member Resource, please Log in


TOPICS IN THIS ARTICLE:

Share this article